GENE LOGIC Announces Gene Discovery Collaboration with Baylor College of Medicine for Prostate Cancer.

COLUMBIA, Md.--(BUSINESS WIRE)--Jan. 13, 1997--GENE LOGIC INC. today announced the establishment of a research collaboration with Baylor College of Medicine in Houston to identify genes associated with the development and progression of prostate cancer. Baylor's Prostate Center maintains an extensive library of tumor and normal prostate cell samples which include documented clinical profiles as well as management techniques employed for each respective patient. GENE LOGIC will evaluate patterns of gene expression and regulation in a broad array of microdissected cancerous and normal prostate tissue samples utilizing its proprietary functional genomics technology, and compare these genomics data with the comprehensive clinical outcomes data. The commercial rights to all genes discovered will be owned by GENE LOGIC. The Company will use these genes as targets for drug and diagnostic product development to improve the treatment and clinical management of prostate cancer.

The tissue samples will be evaluated using GENE LOGIC's Restriction Enzyme Analysis of Differentially-Expressed Sequences (READS(TM)) technology to determine differing gene expression profiles of normal and diseased prostate tissue to determine which genes are associated with disease progression. GENE LOGIC will also utilize its Multiplex Selection of Transcription Factors (MuST(TM)) technique to allow identification of DNA-protein interaction sites and transcription factors that regulate the expression of cancer-causing genes in prostate cells.

"This collaboration will allow us to correlate the gene expression patterns in prostatic tumor cells at varying stages of progression with the vast amount of patient outcomes data we have collected," said Ronald A. Morton, Jr., M.D., Director of Laboratories at the Baylor Prostate Center. "The ability to determine the genetic profile of a patient's prostate at a particular time and compare it to historical outcomes will dramatically improve the physician's ability to choose the most appropriate course of treatment, whether it be surgery, drug therapy or monitoring of disease."

"We are pleased to be working with the Baylor Prostate Center, one of the nation's preeminent prostate centers," said Michael J. Brennan, M.D., Ph.D., President and Chief Executive Officer of GENE LOGIC. "By elucidating the complete profile of gene expression and the degree to which individual genes are expressed and regulated in healthy versus diseased tissues, we hope to identify genetic targets for therapeutic drug development, as well as gain useful data on disease staging that can improve the clinical management of prostate cancer."

The Baylor Prostate Center encompasses basic research and clinical facilities devoted to diseases of the prostate. The Baylor Prostate Center is widely supported by the National Institutes of Health for research programs in both prostate cancer, as well as, benign prostatic hypertrophy and is one of three National Cancer Institute prostate cancer SPORE (specialized programs of research excellence) centers.

GENE LOGIC INC. is a privately-held genomics company based in Columbia, Maryland. The Company plans to establish gene discovery alliances with pharmaceutical and diagnostic companies in the areas of osteoporosis, cancer, cardiovascular disease and CNS disease. Earlier this month, GENE LOGIC initiated a research collaboration with the Center for Clinical and Basic Research in Denmark to discover genes associated with osteoporosis. To date, GENE LOGIC has raised $10 million in financing from private investors, including Oxford Bioscience Partners and Hambro Healthcare International.

CONTACT: Gene Logic Inc.

Mark D. Gessler, Sr. VP/Corporate Development & CFO,

410/309-3100, ext. 109

or

Burns McClellan Inc.

James W. Heins, 212/505-1919